MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. WAY
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Waystar Holding (WAY) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Waystar Holding
NasdaqGS•Healthcare•Health Information Services
$25.07-1.01(-0.04%)Pre-market
Market Cap
$5.09B
P/E
37.7x
P/S
4.2x
P/B
1.3x

Waystar Holding Corp. develops a cloud-based software solution for healthcare payments. Its platform offers financial clearance, patient financial care, claim and payer payment management, denials prevention and recovery, clinical integrity and revenue capture, and analytics and reporting solutions. It primarily serves healthcare industry. The company was founded in 2017 and is headquartered in Lehi, Utah.

B

How this company scores

GoodMetricSide Score: 62/100

Strongest: Cash & Earnings Quality (18/25); weakest: Growth (12/25).

Profitability16/25
Growth12/25
Balance Sheet & Red Flags16/25
Cash & Earnings Quality18/25
Strengths
Strong marginsRising earningsLow leverageCash-backed earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 37.7x5y range 35.7x – 634.2x
P/E 37.7x · below its 6-quarter median

Currently below its 6-quarter median.

P/S · 4.2x5y range 3.9x – 5.8x
P/S 4.2x · near its 6-quarter median

Currently near its 6-quarter median.

P/B · 1.3x5y range 1.0x – 2.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Share Dilution

Red Flag

Shares outstanding increased 11.8% — significant dilution, likely from stock compensation or capital raises.

Price & Volume
Market Cap $5.09B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$1.21B
2Q
Q. Revenue
$319.67M
3Q
TTM EBITDA
$432.42M
2Q
TTM Op. Income
$275.76M
2Q
Q. Op. Income
$76.04M
17%
TTM Net Income
$134.79M
6Q
Q. Net Income
$40.87M
27%
EPS
$0.21
11%
Shares Out.
$191.87M
11%
$1.21B in TTM revenue declined 2.5% YoY, reaching $319.67M last quarter. TTM EBITDA of $432.42M and TTM operating income of $275.76M show growth is flowing through to the bottom line. TTM net income of $134.79M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin
36.8%
1%
Op. Margin
23.8%
1%
Net Margin
12.8%
8%
Op. margin of 23.8% is down 0.2% YoY — costs are rising relative to revenue. Net margin at 12.8% Over the past year, operating margin is down 1% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
37.7x
63%
P/S Ratio
4.2x
26%
P/B Ratio
1.3x
43%
At 37.7x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 4.2x and P/B of 1.3x provide additional context. P/E sits above typical market levels while revenue growth is below 5%. Over the past year, P/E is down 63% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$5.87B
7Q
Cash
$12.64M
3Q
Long-Term Debt
$1.45B
2Q
Book Value
$3.99B
7Q
D/E Ratio
0.4
7Q
Debt/EBITDA
12.4
0%
With $5.87B in assets and $1.45B in long-term debt, D/E is 0.4and book value is $3.99B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 7 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$59.41M
39%
TTM Free Cash Flow
$246.26M
12%
FCF Margin
20.4%
2Q
FCF / Net Income
1.8
5Q
TTM FCF of $246.26M on $59.41M in operating cash flow. The FCF / Net Income ratio of 1.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 12% — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 1.3x
· near its 9-quarter median

Currently near its 9-quarter median.